Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination product** containing Petasites hybridus extract (commonly known as butterbur) and levocetirizine. - **Petasites hybridus extract** is a herbal remedy traditionally used for migraine prophylaxis, allergic rhinitis, and respiratory or gastrointestinal spasms. Its main active components, petasins (sesquiterpene esters), have anti-inflammatory properties. Butterbur acts by inhibiting inflammatory mediators (such as prostaglandins and leukotrienes), blocking L-type voltage-dependent calcium channels, suppressing CGRP (calcitonin gene-related peptide) release, and possibly inhibiting cyclooxygenase-2 (COX-2) activity and expression[1][2]. - **Levocetirizine** is a second-generation antihistamine and selective antagonist of the histamine H1 receptor, commonly used for allergic rhinitis and urticaria. It blocks peripheral H1 receptors, preventing the typical allergic and inflammatory responses triggered by histamine[3]. Combining these agents is rationalized by their complementary mechanisms for managing allergy-related symptoms, with butterbur adding anti-inflammatory and possible antispasmodic effects to levocetirizine’s antihistaminic action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on petasites hybridus extract + levocetirizine.